don't look for much intelligent conversation till the P2B trial starts. Till then, there won't be much to discuss.
seriously? You are going to claim no one wants to be in the trial? I can understand a negative view on the company for whatever reason you fail to articulate, but a trial with PD-1 will have people lined up. IL-12 has no side effects and will not discourage anyone from wanting to participate. Stick to your weekly claim of "going to .20 this week" and avoid the stupid claims you just made.
At the time of the Corporate update for ONCS, there was a panel discussion on developing checkpoint inhibitors. I know which one I would have attended, especially when you can get a corporate update by calling ONCS IR dept.
No one really expects a lot out of the corporate update presentations. It is nice getting the more polished scientific presentation, but I assure you that any institution interested in ONCS gets 1 on 1 with Pierce and Punit
Dr. Pierce is particpating in a discussion followed by a scientific lecture about electroporation. I expect most people are more interested in the science discussions not the corporate overviews.
rather an unimpressive turnout at the conference I'd say. halfway through the day, only 1 presentation with 12-15 attendees who looked mostly bored. Wonder what the issue is that had half the presenting companies removed from the schedule.
no, it is a viral vector delivery. So the Virus is being used to infiltrate the cell. I did think that it could be used in combination with ImmunoPulse because the IL-12 increases their efficiency as I understood it. But they are 3 years or better from that being a concern.
I'm kind of thinking that as with other therapies, it is the fact that they are synthetic, and probably an expensive treatment, that is why the Market cap is higher, has nothing to do with efficacy, or development. Maybe the fact they are spread over more indications.
was it just me, or did it seem that IMDZ is behind ONCS in development? Makes me curious about the disparity in Market Cap.
dyna, you may want to take a look at GLUU, or if you want to stay in bio, ADXS is looking pretty strong right now.
dyna, I don't know. You are correct, but there is always the chance.... Tomorrow is a scientific conference where ONCS will be discussed, April 10th is another, there is always the possibility that a institution takes a big position. I'm staying in, just not paying attention to the daily stuff right now. Good luck.
Yes, P2 expanded interim in Q4, TNBC pilot in Q4, P2B starts Q2, initial data in Q4, Same with the H&N. Also look for some pre-clinical collaborations in the coming months.